Customized phase development

March 23, 2011

German companies instrAction and Protagen have signed a strategic alliance for the development of customized phases for downstream processing of biotherapeutics.

German companies instrAction and Protagen have signed a strategic alliance for the development of customized phases for downstream processing of biotherapeutics.

According to Dr Thomas Schwarz, CEO of Ludwigshafen-based separation matrix design and production company instrAction, their proprietary synthetic chromatography phases perform well compared to commonly used matrices for antibody purification. “The know-how and expertise of Protagen in GMP-compliant protein analysis and related services will be decisive for the development of a portfolio of new tailor-made separation phases for the production of recombinant protein drugs, other biotherapeutics and biosimilars”, says Schwarz.

Protagen is a Dortmund-based, GMP-certified service laboratory for protein analysis. “In order to exploit the full value of this exciting new protein purification technology and to convince customers from pharma process development and production, it is important to provide convincing data sets from feasibility studies,” says Dr Stefan Müllner, the company’s CEO. He says that his company “has all the tools and know-how to support instrAction on its way to become the leading company in protein separation technology”.

For more information visit www.protagen.de and www.instraction.com

Related Content:

News